ASSEMBLY BIOSCIENCES INC (ASMB) Stock Price, Quote, News and Overview
NASDAQ:ASMB - Nasdaq - US0453962070 - Common Stock - Currency: USD
ASMB Quote, Performance and Key Statistics
NASDAQ:ASMB (8/1/2025, 8:21:20 PM)
18.4
+0.47 (+2.65%)
The current stock price of ASMB is 18.4 USD. In the past month the price increased by 1.43%. In the past year, price increased by 28.76%.
ASMB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.43 | 344.84B | ||
| AMGN | AMGEN INC | 14.3 | 159.64B | ||
| GILD | GILEAD SCIENCES INC | 14.62 | 140.79B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.67B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.25 | 60.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 52.39B | ||
| ARGX | ARGENX SE - ADR | 72.69 | 41.24B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.68 | 32.36B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.80B | ||
| INSM | INSMED INC | N/A | 20.62B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.10B | ||
| BIIB | BIOGEN INC | 8.24 | 19.33B |
Related stock screener links
About ASMB
Company Profile
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 73 full-time employees. The company went IPO on 2010-12-17. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points with the aim of achieving finite treatment and functional cures and research programs focused on the discovery of therapeutics to treat devastating viral diseases, including a non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses and a small molecule interferon-α (IFN-α) receptor (IFNAR) agonist targeting HBV and HDV. HPIs are antiviral agents in development for HSV-1 and HSV-2, with a clinically validated mechanism of action. Its HBV, HSV-1, and HSV-2 programs include ABI-6250, ABI-5366, and ABI-1179.
Company Info
ASSEMBLY BIOSCIENCES INC
Two Tower Place, 7Th Floor
South San Francisco CALIFORNIA 94080 US
CEO: John G. McHutchison
Employees: 73
Phone: 18334094583
ASSEMBLY BIOSCIENCES INC / ASMB FAQ
What is the stock price of ASSEMBLY BIOSCIENCES INC today?
The current stock price of ASMB is 18.4 USD. The price increased by 2.65% in the last trading session.
What is the ticker symbol for ASSEMBLY BIOSCIENCES INC stock?
The exchange symbol of ASSEMBLY BIOSCIENCES INC is ASMB and it is listed on the Nasdaq exchange.
On which exchange is ASMB stock listed?
ASMB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ASSEMBLY BIOSCIENCES INC stock?
9 analysts have analysed ASMB and the average price target is 32.3 USD. This implies a price increase of 75.54% is expected in the next year compared to the current price of 18.4. Check the ASSEMBLY BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ASSEMBLY BIOSCIENCES INC worth?
ASSEMBLY BIOSCIENCES INC (ASMB) has a market capitalization of 140.58M USD. This makes ASMB a Micro Cap stock.
How many employees does ASSEMBLY BIOSCIENCES INC have?
ASSEMBLY BIOSCIENCES INC (ASMB) currently has 73 employees.
What are the support and resistance levels for ASSEMBLY BIOSCIENCES INC (ASMB) stock?
ASSEMBLY BIOSCIENCES INC (ASMB) has a support level at 17.9 and a resistance level at 19.43. Check the full technical report for a detailed analysis of ASMB support and resistance levels.
Is ASSEMBLY BIOSCIENCES INC (ASMB) expected to grow?
The Revenue of ASSEMBLY BIOSCIENCES INC (ASMB) is expected to grow by 4.22% in the next year. Check the estimates tab for more information on the ASMB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ASSEMBLY BIOSCIENCES INC (ASMB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ASMB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ASMB, evaluating the profitability, health, valuation and growth aspects
- ASSEMBLY BIOSCIENCES INC (ASMB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ASSEMBLY BIOSCIENCES INC (ASMB) Sales and EPS estimates to see what analysts future expectations are.
- ASSEMBLY BIOSCIENCES INC (ASMB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ASSEMBLY BIOSCIENCES INC (ASMB) Insider and Institutional Ownership to learn about the owners and their transactions.
- ASSEMBLY BIOSCIENCES INC (ASMB) Stock Chart to make your own analysis
- ASSEMBLY BIOSCIENCES INC (ASMB) Latest news and press-releases to stay up to date.
Does ASSEMBLY BIOSCIENCES INC (ASMB) stock pay dividends?
ASMB does not pay a dividend.
When does ASSEMBLY BIOSCIENCES INC (ASMB) report earnings?
ASSEMBLY BIOSCIENCES INC (ASMB) will report earnings on 2025-08-06.
What is the Price/Earnings (PE) ratio of ASSEMBLY BIOSCIENCES INC (ASMB)?
ASSEMBLY BIOSCIENCES INC (ASMB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.23).
What is the Short Interest ratio of ASSEMBLY BIOSCIENCES INC (ASMB) stock?
The outstanding short interest for ASSEMBLY BIOSCIENCES INC (ASMB) is 0.66% of its float. Check the ownership tab for more information on the ASMB short interest.
ASMB Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to ASMB. When comparing the yearly performance of all stocks, ASMB is one of the better performing stocks in the market, outperforming 87.24% of all stocks.
ASMB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ASMB. ASMB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ASMB Financial Highlights
Over the last trailing twelve months ASMB reported a non-GAAP Earnings per Share(EPS) of -6.23. The EPS increased by 42.79% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -40.31% | ||
| ROE | -147.12% | ||
| Debt/Equity | 0 |
ASMB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to ASMB. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 25.32% and a revenue growth 4.22% for ASMB